SYK
Stryker Corporation
$304.69
▼ 1.0%Updated Today 7:15 PM ET
▼ Down 17.5% over the last 12 months
Market Cap
$118.00B
P/E
35.13x
Forward P/E (est.)
30.15x
ROE
15.1%
Revenue Growth
8.8%
EPS Growth
16.5%
Profit Margin
13.2%
FCF Yield
3.0%
Debt / Equity
0.71x
ROIC
29.0%
Interest Coverage
—
Current Ratio
2.11x
Dividend Yield
1.1%
Implied Growth (rev. DCF)
5.2%
Rating Score
52/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what SYK's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. SYK trades near $304.69, below its 50-day average ($313.64) and 200-day average ($351.09). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 46 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. SYK's is $8.08 (~2.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month SYK found buyers near $290.96 (support) and sellers near $322.87 (resistance); its 52-week range is $281.00–$404.87. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.1× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Stryker Corporation (SYK) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $118.00B.
In its latest reported year it generated about $25.12B in revenue and $3.25B in net profit.
Our model rates SYK Neutral (52/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
10.1%
Revenue moved from $17.11B in 2021 to $25.12B in 2025, a 10.1% compound annual growth rate. The most recent year grew a steady 8.8% year over year. Slower, mature growth is common for established businesses.
Gross Margin
64.0%
Operating Margin
19.5%
Net Margin
12.9%
ROE
15.1%
Stryker Corporation keeps about 13.2% of each sales dollar as net profit, with a 64.0% gross margin and 19.5% operating margin. Return on equity is 15.1% and return on invested capital about 29.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$1.77B
Net Debt
-$1.10B
Net cash position
Net Debt / EBITDA
-0.23x
Debt / Equity
0.71x
Leverage: debt-to-equity is 0.7x, with a current ratio of 2.1x. That is a moderate, manageable debt load for most businesses. It carries roughly $1.77B of total debt against $2.88B of cash.
Operating CF
$5.04B
Free Cash Flow
$4.28B
FCF Margin
17.1%
In the latest year Stryker Corporation produced about $5.04B of operating cash flow and $4.28B of free cash flow after capital spending. That is a free-cash-flow yield of about 3.0% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
35.13x
P/S
4.71x
P/B
5.94x
EV / EBITDA
18.26x
SYK trades at 35.1x trailing earnings (about 30.2x on estimated forward earnings), 4.7x sales, and 5.9x book value. Reverse-engineering today's price implies the market expects roughly 5.2% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How SYK stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), SYK ranks #32 of 59 by our overall rating. It trades at a premium versus the sector on earnings (35.1x P/E vs. 25.4x median) with a higher return on equity (15.1% vs. 14.9%) and faster revenue growth (8.8% vs. 7.9%).
P/E vs sector
35.1x
median 25.4x
ROE vs sector
15.1%
median 14.9%
Growth vs sector
8.8%
median 7.9%
Sector rank
#32
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$275.19 – $458.66
vs. $304.69 today · expected CAGR -2% – 9%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $27.38B | $29.84B | $32.53B | $35.45B | $38.64B |
| Net income | $3.56B | $3.88B | $4.23B | $4.61B | $5.02B |
| EPS | $9.28 | $10.12 | $11.03 | $12.02 | $13.10 |
| Share price (low) | $194.95 | $212.50 | $231.62 | $252.47 | $275.19 |
| Share price (high) | $324.92 | $354.17 | $386.04 | $420.78 | $458.66 |
| CAGR (low–high) | -36% / 7% | -16% / 8% | -9% / 8% | -5% / 8% | -2% / 9% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for SYK:
- Strong return on equity (15.1%) shows capital is put to work well.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against SYK:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 35.1x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Stryker Corporation is a large-cap health care business growing at a mature pace, with solid profitability, and a heavier debt load to watch. It trades at 35.1x earnings, which our model scores Neutral (52/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.